Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy
Abstract Objectives To assess immunogenicity and safety of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in juvenile idiopathic arthritis (JIA) patients under conventional DMARDs with or without anti-TNF therapy. The influences of demographic data, disease activity and treatment on immun...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2015-01, Vol.33 (5), p.604-609 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 609 |
|---|---|
| container_issue | 5 |
| container_start_page | 604 |
| container_title | Vaccine |
| container_volume | 33 |
| creator | Aikawa, Nadia E França, Ivan L.A Ribeiro, Ana C Sallum, Adriana M.E Bonfa, Eloisa Silva, Clovis A |
| description | Abstract Objectives To assess immunogenicity and safety of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in juvenile idiopathic arthritis (JIA) patients under conventional DMARDs with or without anti-TNF therapy. The influences of demographic data, disease activity and treatment on immune response and the potential deleterious effects of vaccine on disease itself were also evaluated. Methods 17 JIA patients immediately pre-etanercept (Group 1) and 10 JIA patients on stable dose of methotrexate (Group 2) received one dose of PPV23. All patients were evaluated pre-vaccination, 2 months and 12 months post-vaccination for seven pneumoccocal serotypes. Serology was performed by enzyme immunoassay and the immunogenicity endpoints included seroprotection (SP), seroconversion (SP) and geometric mean concentration of antibodies(GMC). Clinical and laboratorial parameters of JIA were evaluated before and after vaccination. Results Groups 1 and 2 were comparable regarding age, gender, disease duration and other DMARDs use ( p > 0.05). Pre-immunization SP and GMC were alike in patients with and without anti-TNF therapy ( p > 0.05). The frequencies of patients achieving adequate vaccine response (seroconversion in ≥50% of all serotypes) at 2 months (53 vs. 30%, p = 0.424) and 12 months (36 vs. 40%, p = 1.0) were similar in JIA patients with and without anti-TNF therapy. Further comparison of patients with and without adequate response at 2 months revealed no influence of demographic, clinical and laboratorial JIA parameters ( p > 0.05). Serious adverse events were not observed. Conclusions Anti-TNF therapy in JIA patients does not seem to have an additional deleterious effect on short/long-term PPV23 immunogenicity compared to MTX alone and no influence on disease parameters was observed with this vaccine. |
| doi_str_mv | 10.1016/j.vaccine.2014.12.030 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1654696499</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X14016831</els_id><sourcerecordid>1652415628</sourcerecordid><originalsourceid>FETCH-LOGICAL-c551t-2c73f5f6e23bb9a9dae251dd1905a0eece0808751375758be2399cd7dd5d04543</originalsourceid><addsrcrecordid>eNqNkl1vFCEUhidGY2v1J2hIvPFmVmBgPm40TWvVpGpia-IdYeHMLisDU2C22T_pb5Lprpr0Rq84gee854O3KJ4TvCCY1K83i61UyjhYUEzYgtAFrvCD4pi0TVVSTtqHxTGmNSsZwd-PiicxbjDGvCLd4-KIcs4ZZfi4-Hm19iEh6TSy3q3KBGFAZhgm51fgjDJpd_cYZQ857L21_ta4FUprQLQqt9KCS2j0dhdzP2sZjAY0OpgGr7xS0qJDn8g4tJm2WdTmWBs_yrQ2CsmQ1sEkE1G-MFksoslpCEh5l-lkvMsi559Ov55HdGvSGvlwd_pp7juZ8vrzxdxOkOPuafGolzbCs8N5Uny7eHd99qG8_PL-49npZak4J6mkqql63tdAq-Wyk52WkFemNekwlxhAAW5x23BSNbzh7TJzXad0ozXXmHFWnRSv9rpj8DcTxCQGExVYKx34KQpSc1Z3Neu6_0EpI7ymbUZf3kM3fgp5_JliddM0XTvX5ntKBR9jgF6MwQwy7ATBYvaG2IjDzsXsDUGoyN7IeS8O6tNyAP0n67cZMvB2D0De3NZAEFHlD1GgTQCVhPbmnyXe3FNQ1mQXSfsDdhD_TiNiThBXs0FnfxKWNduKVL8AFnvmfw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1646777984</pqid></control><display><type>article</type><title>Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Aikawa, Nadia E ; França, Ivan L.A ; Ribeiro, Ana C ; Sallum, Adriana M.E ; Bonfa, Eloisa ; Silva, Clovis A</creator><creatorcontrib>Aikawa, Nadia E ; França, Ivan L.A ; Ribeiro, Ana C ; Sallum, Adriana M.E ; Bonfa, Eloisa ; Silva, Clovis A</creatorcontrib><description>Abstract Objectives To assess immunogenicity and safety of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in juvenile idiopathic arthritis (JIA) patients under conventional DMARDs with or without anti-TNF therapy. The influences of demographic data, disease activity and treatment on immune response and the potential deleterious effects of vaccine on disease itself were also evaluated. Methods 17 JIA patients immediately pre-etanercept (Group 1) and 10 JIA patients on stable dose of methotrexate (Group 2) received one dose of PPV23. All patients were evaluated pre-vaccination, 2 months and 12 months post-vaccination for seven pneumoccocal serotypes. Serology was performed by enzyme immunoassay and the immunogenicity endpoints included seroprotection (SP), seroconversion (SP) and geometric mean concentration of antibodies(GMC). Clinical and laboratorial parameters of JIA were evaluated before and after vaccination. Results Groups 1 and 2 were comparable regarding age, gender, disease duration and other DMARDs use ( p > 0.05). Pre-immunization SP and GMC were alike in patients with and without anti-TNF therapy ( p > 0.05). The frequencies of patients achieving adequate vaccine response (seroconversion in ≥50% of all serotypes) at 2 months (53 vs. 30%, p = 0.424) and 12 months (36 vs. 40%, p = 1.0) were similar in JIA patients with and without anti-TNF therapy. Further comparison of patients with and without adequate response at 2 months revealed no influence of demographic, clinical and laboratorial JIA parameters ( p > 0.05). Serious adverse events were not observed. Conclusions Anti-TNF therapy in JIA patients does not seem to have an additional deleterious effect on short/long-term PPV23 immunogenicity compared to MTX alone and no influence on disease parameters was observed with this vaccine.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2014.12.030</identifier><identifier>PMID: 25554240</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adolescent ; Age ; Allergy and Immunology ; Anti-TNF ; Antibodies, Bacterial - blood ; Antirheumatic Agents - therapeutic use ; Arthritis ; Arthritis, Juvenile - drug therapy ; Arthritis, Juvenile - immunology ; Child ; Child, Preschool ; Disease ; Drug dosages ; Drug therapy ; Enzyme-Linked Immunosorbent Assay ; Etanercept ; Female ; Gender ; Hospitalization ; Hospitals ; Humans ; Immune response ; Immunization ; Immunogenicity ; Immunoglobulin G - therapeutic use ; Juvenile idiopathic arthritis ; Male ; Methotrexate - therapeutic use ; Patients ; Pneumococcal Infections - prevention & control ; Pneumococcal vaccine ; Pneumococcal Vaccines - administration & dosage ; Pneumococcal Vaccines - adverse effects ; Pneumococcal Vaccines - immunology ; Receptors, Tumor Necrosis Factor - therapeutic use ; Rheumatic diseases ; Seroconversion ; Streptococcus infections ; Streptococcus pneumoniae ; Treatment Outcome ; Tumor Necrosis Factor-alpha - therapeutic use ; Vaccines</subject><ispartof>Vaccine, 2015-01, Vol.33 (5), p.604-609</ispartof><rights>Elsevier Ltd</rights><rights>2014 Elsevier Ltd</rights><rights>Copyright © 2014 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jan 29, 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c551t-2c73f5f6e23bb9a9dae251dd1905a0eece0808751375758be2399cd7dd5d04543</citedby><cites>FETCH-LOGICAL-c551t-2c73f5f6e23bb9a9dae251dd1905a0eece0808751375758be2399cd7dd5d04543</cites><orcidid>0000-0001-8182-7162 ; 0000-0002-7585-4348</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1646777984?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994,64384,64386,64388,72340</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25554240$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aikawa, Nadia E</creatorcontrib><creatorcontrib>França, Ivan L.A</creatorcontrib><creatorcontrib>Ribeiro, Ana C</creatorcontrib><creatorcontrib>Sallum, Adriana M.E</creatorcontrib><creatorcontrib>Bonfa, Eloisa</creatorcontrib><creatorcontrib>Silva, Clovis A</creatorcontrib><title>Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Objectives To assess immunogenicity and safety of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in juvenile idiopathic arthritis (JIA) patients under conventional DMARDs with or without anti-TNF therapy. The influences of demographic data, disease activity and treatment on immune response and the potential deleterious effects of vaccine on disease itself were also evaluated. Methods 17 JIA patients immediately pre-etanercept (Group 1) and 10 JIA patients on stable dose of methotrexate (Group 2) received one dose of PPV23. All patients were evaluated pre-vaccination, 2 months and 12 months post-vaccination for seven pneumoccocal serotypes. Serology was performed by enzyme immunoassay and the immunogenicity endpoints included seroprotection (SP), seroconversion (SP) and geometric mean concentration of antibodies(GMC). Clinical and laboratorial parameters of JIA were evaluated before and after vaccination. Results Groups 1 and 2 were comparable regarding age, gender, disease duration and other DMARDs use ( p > 0.05). Pre-immunization SP and GMC were alike in patients with and without anti-TNF therapy ( p > 0.05). The frequencies of patients achieving adequate vaccine response (seroconversion in ≥50% of all serotypes) at 2 months (53 vs. 30%, p = 0.424) and 12 months (36 vs. 40%, p = 1.0) were similar in JIA patients with and without anti-TNF therapy. Further comparison of patients with and without adequate response at 2 months revealed no influence of demographic, clinical and laboratorial JIA parameters ( p > 0.05). Serious adverse events were not observed. Conclusions Anti-TNF therapy in JIA patients does not seem to have an additional deleterious effect on short/long-term PPV23 immunogenicity compared to MTX alone and no influence on disease parameters was observed with this vaccine.</description><subject>Adolescent</subject><subject>Age</subject><subject>Allergy and Immunology</subject><subject>Anti-TNF</subject><subject>Antibodies, Bacterial - blood</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis</subject><subject>Arthritis, Juvenile - drug therapy</subject><subject>Arthritis, Juvenile - immunology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Disease</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Etanercept</subject><subject>Female</subject><subject>Gender</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Juvenile idiopathic arthritis</subject><subject>Male</subject><subject>Methotrexate - therapeutic use</subject><subject>Patients</subject><subject>Pneumococcal Infections - prevention & control</subject><subject>Pneumococcal vaccine</subject><subject>Pneumococcal Vaccines - administration & dosage</subject><subject>Pneumococcal Vaccines - adverse effects</subject><subject>Pneumococcal Vaccines - immunology</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><subject>Rheumatic diseases</subject><subject>Seroconversion</subject><subject>Streptococcus infections</subject><subject>Streptococcus pneumoniae</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - therapeutic use</subject><subject>Vaccines</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkl1vFCEUhidGY2v1J2hIvPFmVmBgPm40TWvVpGpia-IdYeHMLisDU2C22T_pb5Lprpr0Rq84gee854O3KJ4TvCCY1K83i61UyjhYUEzYgtAFrvCD4pi0TVVSTtqHxTGmNSsZwd-PiicxbjDGvCLd4-KIcs4ZZfi4-Hm19iEh6TSy3q3KBGFAZhgm51fgjDJpd_cYZQ857L21_ta4FUprQLQqt9KCS2j0dhdzP2sZjAY0OpgGr7xS0qJDn8g4tJm2WdTmWBs_yrQ2CsmQ1sEkE1G-MFksoslpCEh5l-lkvMsi559Ov55HdGvSGvlwd_pp7juZ8vrzxdxOkOPuafGolzbCs8N5Uny7eHd99qG8_PL-49npZak4J6mkqql63tdAq-Wyk52WkFemNekwlxhAAW5x23BSNbzh7TJzXad0ozXXmHFWnRSv9rpj8DcTxCQGExVYKx34KQpSc1Z3Neu6_0EpI7ymbUZf3kM3fgp5_JliddM0XTvX5ntKBR9jgF6MwQwy7ATBYvaG2IjDzsXsDUGoyN7IeS8O6tNyAP0n67cZMvB2D0De3NZAEFHlD1GgTQCVhPbmnyXe3FNQ1mQXSfsDdhD_TiNiThBXs0FnfxKWNduKVL8AFnvmfw</recordid><startdate>20150129</startdate><enddate>20150129</enddate><creator>Aikawa, Nadia E</creator><creator>França, Ivan L.A</creator><creator>Ribeiro, Ana C</creator><creator>Sallum, Adriana M.E</creator><creator>Bonfa, Eloisa</creator><creator>Silva, Clovis A</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8182-7162</orcidid><orcidid>https://orcid.org/0000-0002-7585-4348</orcidid></search><sort><creationdate>20150129</creationdate><title>Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy</title><author>Aikawa, Nadia E ; França, Ivan L.A ; Ribeiro, Ana C ; Sallum, Adriana M.E ; Bonfa, Eloisa ; Silva, Clovis A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c551t-2c73f5f6e23bb9a9dae251dd1905a0eece0808751375758be2399cd7dd5d04543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Age</topic><topic>Allergy and Immunology</topic><topic>Anti-TNF</topic><topic>Antibodies, Bacterial - blood</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis</topic><topic>Arthritis, Juvenile - drug therapy</topic><topic>Arthritis, Juvenile - immunology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Disease</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Etanercept</topic><topic>Female</topic><topic>Gender</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Juvenile idiopathic arthritis</topic><topic>Male</topic><topic>Methotrexate - therapeutic use</topic><topic>Patients</topic><topic>Pneumococcal Infections - prevention & control</topic><topic>Pneumococcal vaccine</topic><topic>Pneumococcal Vaccines - administration & dosage</topic><topic>Pneumococcal Vaccines - adverse effects</topic><topic>Pneumococcal Vaccines - immunology</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><topic>Rheumatic diseases</topic><topic>Seroconversion</topic><topic>Streptococcus infections</topic><topic>Streptococcus pneumoniae</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - therapeutic use</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aikawa, Nadia E</creatorcontrib><creatorcontrib>França, Ivan L.A</creatorcontrib><creatorcontrib>Ribeiro, Ana C</creatorcontrib><creatorcontrib>Sallum, Adriana M.E</creatorcontrib><creatorcontrib>Bonfa, Eloisa</creatorcontrib><creatorcontrib>Silva, Clovis A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aikawa, Nadia E</au><au>França, Ivan L.A</au><au>Ribeiro, Ana C</au><au>Sallum, Adriana M.E</au><au>Bonfa, Eloisa</au><au>Silva, Clovis A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2015-01-29</date><risdate>2015</risdate><volume>33</volume><issue>5</issue><spage>604</spage><epage>609</epage><pages>604-609</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Abstract Objectives To assess immunogenicity and safety of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in juvenile idiopathic arthritis (JIA) patients under conventional DMARDs with or without anti-TNF therapy. The influences of demographic data, disease activity and treatment on immune response and the potential deleterious effects of vaccine on disease itself were also evaluated. Methods 17 JIA patients immediately pre-etanercept (Group 1) and 10 JIA patients on stable dose of methotrexate (Group 2) received one dose of PPV23. All patients were evaluated pre-vaccination, 2 months and 12 months post-vaccination for seven pneumoccocal serotypes. Serology was performed by enzyme immunoassay and the immunogenicity endpoints included seroprotection (SP), seroconversion (SP) and geometric mean concentration of antibodies(GMC). Clinical and laboratorial parameters of JIA were evaluated before and after vaccination. Results Groups 1 and 2 were comparable regarding age, gender, disease duration and other DMARDs use ( p > 0.05). Pre-immunization SP and GMC were alike in patients with and without anti-TNF therapy ( p > 0.05). The frequencies of patients achieving adequate vaccine response (seroconversion in ≥50% of all serotypes) at 2 months (53 vs. 30%, p = 0.424) and 12 months (36 vs. 40%, p = 1.0) were similar in JIA patients with and without anti-TNF therapy. Further comparison of patients with and without adequate response at 2 months revealed no influence of demographic, clinical and laboratorial JIA parameters ( p > 0.05). Serious adverse events were not observed. Conclusions Anti-TNF therapy in JIA patients does not seem to have an additional deleterious effect on short/long-term PPV23 immunogenicity compared to MTX alone and no influence on disease parameters was observed with this vaccine.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>25554240</pmid><doi>10.1016/j.vaccine.2014.12.030</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-8182-7162</orcidid><orcidid>https://orcid.org/0000-0002-7585-4348</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2015-01, Vol.33 (5), p.604-609 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1654696499 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Adolescent Age Allergy and Immunology Anti-TNF Antibodies, Bacterial - blood Antirheumatic Agents - therapeutic use Arthritis Arthritis, Juvenile - drug therapy Arthritis, Juvenile - immunology Child Child, Preschool Disease Drug dosages Drug therapy Enzyme-Linked Immunosorbent Assay Etanercept Female Gender Hospitalization Hospitals Humans Immune response Immunization Immunogenicity Immunoglobulin G - therapeutic use Juvenile idiopathic arthritis Male Methotrexate - therapeutic use Patients Pneumococcal Infections - prevention & control Pneumococcal vaccine Pneumococcal Vaccines - administration & dosage Pneumococcal Vaccines - adverse effects Pneumococcal Vaccines - immunology Receptors, Tumor Necrosis Factor - therapeutic use Rheumatic diseases Seroconversion Streptococcus infections Streptococcus pneumoniae Treatment Outcome Tumor Necrosis Factor-alpha - therapeutic use Vaccines |
| title | Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T13%3A42%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short%20and%20long-term%20immunogenicity%20and%20safety%20following%20the%2023-valent%20polysaccharide%20pneumococcal%20vaccine%20in%20juvenile%20idiopathic%20arthritis%20patients%20under%20conventional%20DMARDs%20with%20or%20without%20anti-TNF%20therapy&rft.jtitle=Vaccine&rft.au=Aikawa,%20Nadia%20E&rft.date=2015-01-29&rft.volume=33&rft.issue=5&rft.spage=604&rft.epage=609&rft.pages=604-609&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2014.12.030&rft_dat=%3Cproquest_cross%3E1652415628%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1646777984&rft_id=info:pmid/25554240&rft_els_id=S0264410X14016831&rfr_iscdi=true |